|
|
|
|
||
|
||
|
Vol. 7, Nos. 1-43 pp. 1-1268 Jan. 2-Oct. 30 , 2009 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
JAPAN
– Generic manufacturing allowed before patent expiration, 487
– AndroGel, class actions seek to recoup charges paid due to collusion between brand name and generic firms, transferred to Ga. federal court (C.D. Cal.), 435
– Blood factor concentrates, Taiwanese hemophiliacs suits may proceed in Cal. (N.D. Ill.), 96 – Elidel suits remanded (D.N.J.), 734 – Heparin adverse reaction, suit remanded to state court (S.D. Ala.), 255 – Lipitor infringement suit stayed over jurisdiction issues (N.D. Ill.), 703 – Reglan liability suit properly removed to federal court (E.D. Pa.), 529 – Risperdal, jurisdiction lacking to hear patent counterclaims (U.S., rev den), 340 Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
